Eli Lilly and Co (LLY) has received a top rating of 100% from Validea's Quantitative Momentum Investor model, based on Wesley Gray's strategy. This strong endorsement, driven by the large-cap biotechnology and drugs company's robust and consistent intermediate-term relative performance, underlying fundamentals, and valuation, indicates strong interest from this momentum-focused investment approach.
Eli Lilly and Co (LLY) has achieved a top rating of 100% from Validea's Quantitative Momentum Investor model, which is based on Wesley Gray's established strategy. This perfect score indicates a "strong interest" in LLY, as per the model's threshold for scores above 90%. This endorsement positions LLY favorably within the large-cap Biotechnology & Drugs sector. The robust rating is attributed to LLY's strong and consistent intermediate-term relative performance, coupled with solid underlying fundamentals and attractive valuation. The company successfully passed key criteria including "DEFINE THE UNIVERSE," "TWELVE MINUS ONE MOMENTUM," and "RETURN CONSISTENCY," while "SEASONALITY" was deemed neutral. These factors collectively underscore the stock's quantitative appeal. The overall sentiment surrounding this development is "strongly positive" and "bullish" for LLY, reflected by a sentiment score of 0.8. While the market impact score is moderate at 0.45, this strong quantitative signal from a respected momentum strategy suggests potential for continued positive investor positioning and technical flows. This analysis aligns with themes of Company Fundamentals, Analyst Insights, and Market Technicals.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment
